1
www.brainstorm-cell.com
BrainStorm Cell Therapeutics Inc.
(OTCBB: BCLI)
BrainStorm is a leading developer of stem cell
technologies to provide treatments for
currently incurable neurodegenerative
diseases.
The Company is focused on developing NTF
cells from the patient's own bone marrow in
order to treat, Parkinson, ALS, and Spinal
Cord Injury.
www.brainstorm-cell.com
Parkinson Disease
PD is a degenerative disorder of the central
nervous system (loss of dopamine-containing
nerve cells) that often impairs the sufferer's
motor skills, speech and other functions.
 Large and growing population of Parkinson Disease patients
(4 M in the Western world).
 Heavy social burden (according to NINDS, $26B in the U.S.
annually).
 Disease anatomy and pathology is well known, although
causes are still obscure.
 Affects a clearly defined region of the brain, the substantia
nigra.
3
Amyotrophic Lateral Sclerosis Disease
ALS (sometimes called Lou Gehrig's disease) is a
progressive, usually fatal, neurodegenerative
disease caused by the degeneration of motor
neurons, the nerve cells in the central nervous
system that control voluntary muscle movement.
 5,600 people in the U.S. are diagnosed with ALS Amyotrophic Lateral
Sclerosis (Lou Gehrig's Disease) each year. Total 30,000 patients in
the US. & 100,000 around the world.
 Fatal progressive loss of motor neurons in brain and spinal cord.
 Leads to gradual loss of movement ability, culminating in death.
 One approved drug – Rilutek (Riluzole) affords only an additional
few months of life.
 Pressing need for new effective therapies.
4
Advantage of Cell Therapy
Cell technologies may offer a major
improvement over medication, as
they target the diseased cell or organ
and replace it with a healthy
alternative.
Adult Stem Cells
Adult stem cells are undifferentiated cells, found
throughout the body after embryonic development,
that multiply by cell division to replenish dying cells
and regenerate damaged tissues.
Adult Stem Cells (From Bone Marrow)
Advantages:
6
 Non tumor forming.
 More than 40 years safety record.
 Harvested from patient – therapy
does not require immunosupression.
 Unlike embryonic stem cells, the
use of adult stem cells in research
and therapy is not considered to be
controversial as they are derived
from adult tissue samples rather
than human embryos.
Brainstorm’s strategy
NurOwn™ Therapeutic Technology
Autologous Bone Marrow-derived Stem Cell Therapy
BrainStorm
Patent
Into neurotrophic factors
(NTF) secreting cell
BrainStorm
know-how
Bone marrow
aspiration
7
www.brainstorm-cell.com
Intellectual Property
 Trademark filed for NurOwnTM in the US
 3 Patents pending
Bone
Marrow
Stem Cells
1. PCT covering methods of generating
Dopamine-producing neural cells
from bone marrow stem cells;
Currently in national phase (Patent
granted in Singapore)
2.
PCT covering methods of generating
oligodendrocytes from bone marrow
stem cells; Currently in national phase
3. PCT covering methods of generating
GDNF-producing cells from bone
marrow stem cells; Currently in
Neuron
Oligodendrocyte
national phase
8
www.brainstorm-cell.com
NTF cells
Business Model
Hematology:
Bone Marrow
aspirate
NurOwnTM
Patient
population
Insurance payment
to medical center
Neurosurgery:
NurOwn™
Cells
implantation
9
www.brainstorm-cell.com
Medical center purchases
BrainStorm cell processing
services
BrainStorm Financial Summary
Stock Symbol: OTCBB:BCLI
 Shares outstanding: 55.3M
 Current price of stock : ~ $0.1
 52 week price range: $0.07-$0.76
Market capitalization: ~ $5M
 Approximate Public Float: 17M shares
 Monthly current burn rate : $150K
 Seeking for $10M to complete phase I and II clinical trials in ALS
and phase I clinical trials in Parkinson.
10
www.brainstorm-cell.com
Safe Harbor Disclaimer
This presentation may contain certain ‘forward-looking
statements’. All statements, other than statements of historical
fact, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in
the future are forward-looking statements. Such statements are
based upon certain assumptions and assessments made by our
management in light of their experience and their perception of
historical trends, current conditions, expected future
developments and other factors they believe to be appropriate.
The forward-looking statements included in this presentation are
also subject to a number of material risks and uncertainties. We
caution investors not to place undue reliance on the forwardlooking statements contained in this presentation.
We would advise reading our annual report filed with the United
States Securities and Exchange Commission on Form 10-K for a
more detailed description of these risks.
11
www.brainstorm-cell.com
12
www.brainstorm-cell.com